In this context, advances in heteroaryl medicinal chemistry have facilitated the development of selective kinase inhibitors capable of precisely targeting emerging regulators such as DYRK1B, underscoring its therapeutic potential in addressing the multifactorial nature of metabolic disorders. Here, DYRK1B is linked to Other metabolic disease.